MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Effects of the Lee Silverman Voice Treatment (LSVT LOUD ®) on Facial Expressivity in Individuals with Parkinson’s Disease (PD) as a function of Emotional Valence

    A. Bono, K. Scorpio, R. Stafford, M. Halfacre, E. Murray, J. Twaite, K. Alterescu, J. Spielman, A. Halpern, L. Ramig, J. Borod (Flushing, NY, USA)

    Objective: To examine the effect of LSVT LOUD (Ramig et al., 2011) on facial expressivity in PD as a function of emotional valence. Background: Research…
  • 2018 International Congress

    Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

    J. Pagonabarraga, E. Tolosa, J. Ferreira, A. Lees, E. Arbe, J. Rocha, P. Soares-da-Silva (Barcelona, Spain)

    Objective: To elucidate which levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients were at higher risk for developing dyskinesia when starting opicapone (OPC) 50mg or entacapone (ENT).…
  • 2018 International Congress

    Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Responder analyses from the BIPARK-I double-blind experience

    J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the proportion of patients (ie, responders) achieving at least a 1-h reduction…
  • 2018 International Congress

    A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s disease: Study Design

    T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Chicago, IL, USA)

    Objective: To assess the safety and tolerability of nilotinib (150-300 mg QD) in moderate/advanced and early/de novo Parkinson disease (PD) participants. Background: Studies in cell…
  • 2018 International Congress

    Delayed-onset Edema Surrounding Deep Brain Stimulation Leads: Insights From A Case Series and Literature Review

    Y. Hu (Guangzhou, China)

    Objective: We report a case that showed Postoperative cerebral edema around a deep brain stimulation (DBS) electrode and review the literature to explore its possible causes. Background: Deep brain…
  • 2018 International Congress

    Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease

    V. Pitz, N. Malek, K. Grosset, D. Grosset (Glasgow, United Kingdom)

    Objective: To examine the L-dopa-response (improvement in motor symptoms) in published cases of pathologically confirmed Parkinson’s disease (PD). Background: L-dopa responsiveness supports the diagnosis of…
  • 2018 International Congress

    Effectiveness and safety of acupuncture in the treatment of Parkinson’s disease: A systematic review and meta-analysis of randomized controlled trials

    CN. Ko, SU. Park, SY. Cho, JM. Park (Seoul, Korea)

    Objective: This study aimed to examine the effectiveness and safety of acupuncture in the treatment of Parkinson’s disease (PD). Background: Background: Several previous studies have…
  • 2018 International Congress

    Impact of SYN120 (a Dual 5-HT6/5-HT2A antagonist) on psychiatric symptoms in patients with Parkinson’s disease dementia: Results from a Phase 2a Study

    D. Weintraub (Philadelphia, PA, USA)

    Objective: To assess the psychiatric effects of SYN120 in patients with Parkinson's disease dementia (PDD). Background: SYN120 is a dual antagonist of serotonin (5-HT6 and…
  • 2018 International Congress

    The effects of bright light therapy on depression, sleep and circadian rhythm in patients with Parkinson’s disease and a depressive disorder: Results of a double-blind randomized controlled trial

    S. Rutten, C. Vriend, J. Smit, H. Berendse, E. van Someren, A. Hoogendoorn, J. Twisk, Y. vd Werf, O. vd Heuvel (Amsterdam, Netherlands)

    Objective: The aim of this study was to assess the efficacy of Bright Light Therapy (BLT) in reducing depressive symptoms in patients with Parkinson’s disease…
  • 2018 International Congress

    GASTROPARK: Multicenter study on the efficacy of dopamine agonists for gastrointestinal symptoms in Parkinson’s disease

    J. Martinez Castrillo, A. Alonso Canovas, G. Fernandez Pajarin, L. Vela Desojo, J. Garcia Caldentey, P. Sanchez Alonso, M. Fernandez Moreno, M. Mata, J. Herreros Rodriguez, J. Infante, J. Ruiz Martinez, C. Ruiz Huete, S. Fanjul Arbos, P. Garcia Ruiz (Madrid, Spain)

    Objective: Main: To assess the modification of gastrointestinal symptoms in patients with Parkinson's disease before and after the introduction of dopamine agonists. Secondary: (1) To…
  • « Previous Page
  • 1
  • …
  • 1217
  • 1218
  • 1219
  • 1220
  • 1221
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley